Otsuka Slaps Amneal With IP Suit Over Generic Abilify

Law360, New York (April 27, 2012, 8:13 PM EDT) -- Japanese drugmaker Otsuka Pharmaceuticals Co. Ltd. on Thursday launched a patent infringement suit against Amneal Pharmaceuticals LLC, challenging the rival's attempt to score U.S. approval of a generic version of anti-psychotic drug Abilify.

In a complaint filed in New Jersey federal court, Otsuka argued that Amneal and two of its affiliates, including one in India, had infringed its patent by submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration.

"Amneal has infringed at least one claim of the '257 patent by submitting, or causing to be submitted to the FDA, ANDA No. 20-3906 seeking approval for the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!